Skip to main navigation
Skip to search
Skip to main content
University of Luebeck Home
English
Deutsch
Home
Research Units
Experts
Publications
Projects
Datasets
Prizes
Spin-Offs
Activities
Media
Search by expertise, name or affiliation
The value of anti-angiogenics in breast cancer therapy
Malgorzata Banys-Paluchowski
*
, Tanja Fehm, Volkmar Müller
*
Corresponding author for this work
Clinic of Gynecology and Obstetrics
University of Düsseldorf
University Hospital Hamburg-Eppendorf
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The value of anti-angiogenics in breast cancer therapy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Neoplasm
100%
Breast Cancer
100%
Antiangiogenic
100%
Angiogenesis Inhibitor
66%
Angiogenesis
66%
Bevacizumab
66%
Metastatic Breast Cancer
66%
Tumor Cell
33%
Tyrosine-Kinase Inhibitor
33%
Sorafenib
33%
Cancer Growth
33%
Neoadjuvant Therapy
33%
Vasculotropin
33%
Vascular Bundle
33%
Sunitinib
33%
Pazopanib
33%
Pharmacology, Toxicology and Pharmaceutical Science
Antiangiogenic
100%
Neoplasm
100%
Breast Cancer
100%
Metastatic Breast Cancer
50%
Protein Tyrosine Kinase Inhibitor
25%
Pazopanib
25%
Vasculotropin
25%
Cancer Growth
25%
Sorafenib
25%
Sunitinib
25%
Immunology and Microbiology
Angiogenesis
100%
Angiogenesis Inhibitor
100%
Tyrosine
50%
Blood Vessel
50%
Tumor Cell
50%
Sorafenib
50%